O uso de estatinas no Acidente Vascular Cerebral
revisão de literatura
DOI:
https://doi.org/10.34024/rnc.2011.v19.8411Palavras-chave:
Colesterol, Endotélio Vascular, Isquemia, Radicais LivresResumo
Objetivo. Este trabalho objetivou realizar uma revisão da associação entre estatinas e AVC. Método. Foi realizada uma pesquisa bibliográfica no banco de dados MEDLINE, LILACS e no portal CAPES para identificar artigos relevantes publicados entre 1997 e 2010 que relatassem tal associação. Os artigos foram selecionados segundo os critérios de Oxman e Guyatt e classificados quanto à sua metodologia. Seguindo os critérios anteriores, selecionaram-se 52 artigos, por meio dos quais foram constatados os efeitos inibidores das estatinas na síntese do colesterol. Resultados. Confirmou-se, também, o efeito vasodilatador e antioxidante das estatinas, pois seu uso proporciona a redução na formação de radicais livres, favorece a vasodilatação e diminui a degradação do óxido nítrico. Conclusão. Em vista dos resultados apresentados, confirmaram-se os efeitos benéficos do uso de estatinas em pacientes com AVC.
Referências
Riveira OCE, Pérez RGE. Statins in: primary and secondary prevention. Rev Med Univ Nac Colomb 2006;54:301-2.
Sanossian N, Ovbiagele B. Drug insight: translating evidence on statin therapy into clinical benefits. Nat Cl Prac Neurol 2008;1:43-9. DOI: https://doi.org/10.1038/ncpneuro0705
Linarelli MCB, Pott jr. H. Estatinas: uma revisão sobre os aspectos vasculares. Rev Ciên Med. 2008;17:43-52.
Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999;30: 1969-73. DOI: https://doi.org/10.1161/01.STR.30.9.1969
Endres M, Laufus U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004:35:2708-11. DOI: https://doi.org/10.1161/01.STR.0000143319.73503.38
Montaner J, Chacón P, Krupinski J, Rubio F, Millán M, Molina CA, et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008;15:82-90. DOI: https://doi.org/10.1111/j.1468-1331.2007.02015.x
Oxman AD, Guyatt GH. Guidelines for reading literature reviews. CMAJ 1988; 135: 697-703.
Guyatt GH, Sinclair J, Cook DJ, Glasziou P. Users’ guides to the medical literature. JAMA 1999;19:1843-1863.
Furlan AD. Em busca de evidência para a prática médica diária. Ac Fisi 2000;7:20-8.
Girardi JM, Girardi FA, Peters VM. Endotélio vascular e efeitos das estatinas. HU Rev 2006;1:21-5.
Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997;28:2315-20. DOI: https://doi.org/10.1161/01.STR.28.11.2315
Veillard NR, Mach F. Statins: the new aspirin? Cell Mol Life Sc 2002;59:1771-86. DOI: https://doi.org/10.1007/PL00012505
Politei JM. Can we use statins to prevent stroke in Fabry disease. J Inherit Metab Dis 2009;32; 481-487. DOI: https://doi.org/10.1007/s10545-009-1156-2
Elkind MSV. Statins as acute-stroke treatment. Int J Stroke 2006;1:224-5. DOI: https://doi.org/10.1111/j.1747-4949.2006.00061.x
Dickinson CJ. Strokes and their relationship to hypertension. Curr Opin Nephrol Hypertens 2003;12:91-6. DOI: https://doi.org/10.1097/00041552-200301000-00015
Guerra LC, Moreno MCF, Chozas JML, Hernández MDJ. Statins and stroke prevention: what an internist should know. Eur J Int Med 2008;19:8-14. DOI: https://doi.org/10.1016/j.ejim.2007.05.010
Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, doubleblind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946–50. DOI: https://doi.org/10.1161/01.STR.28.5.946
Crouse 3rd JR, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997;157:1305-10. DOI: https://doi.org/10.1001/archinte.1997.00440330039004
Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313–21. DOI: https://doi.org/10.1001/jama.1997.03550040069040
Girot M, Cordoliani MAM, Deplanque D, Hénon H, Lucas C, Leys D. Secondary prevention after ischemic stroke. J Neurol 2005;252:14-20. DOI: https://doi.org/10.1007/s00415-005-0591-8
Hankey GJ. Statins after transient ischaemic attack and ischaemic stroke. Lancet Neurol 2006;5:810-2. DOI: https://doi.org/10.1016/S1474-4422(06)70559-2
White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JDG, Hunt D, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000;343:317-26.
Spencer DC, Karceski S. About stroke. Neurology 2009;72:112-3.
Bautista LE. Blood-pressure lowering effects of statins: who benefits. J Hypertens 2009;27:478-1484. DOI: https://doi.org/10.1097/HJH.0b013e32832b1e78
Varona JF, Bermejo F, Guerra JM, Molina JA. Long-term prognosis of ischemic stroke in young adults. J Neurol 2004;251:1507-14. DOI: https://doi.org/10.1007/s00415-004-0583-0
Ovbiagele B, Kidwell CS, Saver JL. Expanding indications for statins in cerebral ischemia. Arch Neurol 2005;62: 67-72. DOI: https://doi.org/10.1001/archneur.62.1.67
Blanco M, Nombela F, Castellanos M, Rodriguez-Yánes M, Garcia-Gil M, Leira R, et al. Statin treatment withdrawal in isquemic stroke. Neurology 2007;69:904-10. DOI: https://doi.org/10.1212/01.wnl.0000269789.09277.47
Matínez-Sanchez P, Riveira-Ordónez C, Fuentes B, Ortega-Casarrubios MA, Idrovo L, Díez-Tejedor E. The beneficial effect of statins treatment by stroke subtype. Eur J Neurol 2009;16:127-33. DOI: https://doi.org/10.1111/j.1468-1331.2008.02370.x
Stead LG, Vaidyanathan L, Kumar G, Bellolio MF, Brown RD, Suravaram S, et al. Statins in ischemic stroke: just low-density lipoprotein lowering or more? J Stroke Cerebrovasc Diseases 2009;2:124-7. DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2008.09.016
Mok VCT, Lam WWM, Fan YH, Wong A, Wing Ng P, Tsoi TH, et al. Effects of statins on the progression of the cerebral white matter lesion. J Neurol 2009;256:750-7. DOI: https://doi.org/10.1007/s00415-009-5008-7
Markus HS. Current treatments in neurology: stroke. J Neurol 2005;252:260-7. DOI: https://doi.org/10.1007/s00415-005-0736-9
Aslanyan S, Weir CJ, Mclnnes GT, Reid JL, Walters MR, Lees KR. Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. Euro J Neurol 2005;12:493-8. DOI: https://doi.org/10.1111/j.1468-1331.2005.01049.x
Pyõrâlâ K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, et al. The Scandinavian Sinvastatin Survival Study Group. Reduction of cardiovascular events by sinvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome. Diab Care 2004;7:1735-40. DOI: https://doi.org/10.2337/diacare.27.7.1735
Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the cholesterol and recurrent events (CARE) study. Circulation 1999;99: 216-23. DOI: https://doi.org/10.1161/01.CIR.99.2.216
White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JDG, Hunt D, et al. Pravastatin therapy and the risk of stroke (LIPID STUDY). N Engl J Med 2000;343:317-26. DOI: https://doi.org/10.1056/NEJM200008033430502
Guerra LC, Alvarez-Suero J. Statins in the secondary prevention of stroke: risks or beneficts? Euro J Int Med. 2009;20:22. DOI: https://doi.org/10.1016/j.ejim.2008.07.016
Bellosta S, Paoletti R, Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109:50-7. DOI: https://doi.org/10.1161/01.CIR.0000131519.15067.1f
Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008;178:576-84. DOI: https://doi.org/10.1503/cmaj.070675
Kruger PS. Statins and sepsis. Br J Anaesth 2008;100:862. DOI: https://doi.org/10.1093/bja/aen114
Martí-Fàbegras J, Gomis M, Arboix A, Aleu A, Pagobarraga J, Belvís R, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004;35:1117-21. DOI: https://doi.org/10.1161/01.STR.0000125863.93921.3f
Perreault S, Ellia L, Dragomir A, Côté R, Blais L, Bérard A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med 2009;122:647-55. DOI: https://doi.org/10.1016/j.amjmed.2009.01.032
Deambrosis P, Terrazzani G, Walley T, Bader G, Giusti P, Debetto P, et al. Beneficts of statins in daily practice? A six-year retrospective observational study. Pharmacol Res 2009;60;597-401. DOI: https://doi.org/10.1016/j.phrs.2009.06.009
Amarenco P, Bogousslavsky J, Callahan A. Stroke prevention by aggressive reduction in cholesterol levels investigators. High-dose atorvastatin after stroke or transient ischemic attack (SPARCL). N Engl J Med 2006;355: 549-59. DOI: https://doi.org/10.1056/NEJMoa061894
Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KAA, Granger CB, et al. Association of statin therapy with outcomes of acute coronary syndromes: The GRACE study. Ann Intern Med 2004;140:857-66. DOI: https://doi.org/10.7326/0003-4819-140-11-200406010-00006
Sever PS, Dahlõf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58. DOI: https://doi.org/10.1016/S0140-6736(03)12948-0
MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomized placebo-controlled trial (HPS STUDY). Lancet 2002;360:7-22. DOI: https://doi.org/10.1016/S0140-6736(02)09327-3
Sheperd J, Blauw GJ, Murphy MB, Bollen ELE, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30. DOI: https://doi.org/10.1016/S0140-6736(02)11600-X
Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study. Stroke 2001;32:1112-5. DOI: https://doi.org/10.1161/01.STR.32.5.1112
Li G, Larson EB, Sonnem JA, Shofer JB, Petrie EC, Schantz A, et al. TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2008;69:878-85. DOI: https://doi.org/10.1212/01.wnl.0000277657.95487.1c
Stepién K, Tomaszewski M, Czuczwar SJ. Neuroprotective properties of statins. Pharmacol Rep 2005;57:561-9.
Orr JD. Statins in the spectrum of neurologic disease. Curr Atheroscleros Rep 2006;10:11-8.
Green RC, McNagny SE, Jayakumar P, Cupples LA, Benke K, Farrer LA. The MIRAGE Study Group. Statins use and risk of Alzheimer`s disease: the MIRAGE study. Alzheimer Dement 2006;2:96-103. DOI: https://doi.org/10.1016/j.jalz.2006.02.003
Lo EG, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosc 2003; 4:399-415. DOI: https://doi.org/10.1038/nrn1106
Mouhaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009;181:E11-8. DOI: https://doi.org/10.1503/cmaj.081785
Eichel R, Khoury ST, Ben-Hur T, Paniri R, Leker RR. Prior use of statins and outcome in patients with intracerebral haemorrhage. Euro J Neurol 2010;17;78-83. DOI: https://doi.org/10.1111/j.1468-1331.2009.02747.x
